Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Prognostic Value of Resistance Proteins in Plasma Cells From Multiple Myeloma Patients Treated With Bortezomib

Pawel Robak
,
J.; Szemraj
ORCID logo ,
D.; Mikulski
,
I.; Drozdz
ORCID logo ,
K; Juszczak
,
D. Jarych
,
W.; Robak
,
K; Kościelny
ORCID logo ,
W.; Fendler
,
T.; Robak
* ORCID logo
Version 1 : Received: 12 August 2021 / Approved: 13 August 2021 / Online: 13 August 2021 (08:43:42 CEST)

A peer-reviewed article of this Preprint also exists.

Robak, P.; Szemraj, J.; Mikulski, D.; Drozdz, I.; Juszczak, K.; Jarych, D.; Misiewicz, M.; Kościelny, K.; Fendler, W.; Robak, T. Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. J. Clin. Med. 2021, 10, 5028. Robak, P.; Szemraj, J.; Mikulski, D.; Drozdz, I.; Juszczak, K.; Jarych, D.; Misiewicz, M.; Kościelny, K.; Fendler, W.; Robak, T. Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. J. Clin. Med. 2021, 10, 5028.

Abstract

While multiple myeloma (MM) treatment with proteasome inhibitors and other agents yields encouraging results, primary and secondary resistance remains an emerging problem. An important factor in such treatment resistance is the overexpression of several proteins. The present study comprehensively evaluates the expression of POMP, PSMB5, NRF2, XBP1, cMAF and MAFb proteins in plasma cells isolated from the bone marrow of 39 MM patients treated with bortezomib-based regimens using enzyme-linked immunosorbent assay (ELISA). The proteins were selected on the basis of previous laboratory and clinical studies in bortezomib treated MM patients. It was found that the expression of the investigated proteins did not significantly differ between bortezomib-sensitive and bortezomib-refractory patients. However, the expression of some proteins correlated with overall survival (OS); this was significantly shorter in patients with higher POMP expression (HR 2.8, 95% CI: 1.1-7.0, p = 0.0277) and longer in those with higher MAFB expression (HR 0.32, 95% CI: 0.13-0.80, p = 0.0147). Our results indicate that high expression of POMP and MAFB in MM plasma cells may serve as predictors of OS in MM patients treated with bortezomib-based regimens. However, further studies are needed to determine the role of these factors in effective strategies for improving anti-myeloma therapy.

Keywords

bortezomib; cMAF; MAFb; multiple myeloma; POMP; prognosis; PFS; survival; OS

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.